Supplementary Figure 1 from EZH2 Inhibition Promotes Tumor Immunogenicity in Lung Squamous Cell Carcinomas

Supplementary Figure 1 shows changes in NGFR and CD274 (PD-L1) gene and protein expression in human lung cancer cell lines in response to EZH2 inhibitor and interferon-gamma treatment.